Please login to the form below

Not currently logged in
Email:
Password:

spinal muscular atrophy

This page shows the latest spinal muscular atrophy news and features for those working in and with pharma, biotech and healthcare.

FDA starts review of Biogen’s Tecfidera follow-up for MS

FDA starts review of Biogen’s Tecfidera follow-up for MS

That includes spinal muscular atrophy therapy Spinraza (nusinersen), which made $1.7bn in sales last year but could face stiff competition from Novartis/AveXis’ one-off gene therapy Zorgensma.

Latest news

More from news
Approximately 6 fully matching, plus 33 partially matching documents found.

Latest Intelligence

  • Drug launches to watch in 2019 Drug launches to watch in 2019

    The next step in this process is the launch of Zolgensma (AveXis) – the gene therapy for spinal muscular atrophy (SMA) which is now filed with the FDA and EMA, and is

  • No incentive for a cure No incentive for a cure

    to 12-week course. And Spinraza from Biogen, the first ever disease-modifying treatment for spinal muscular atrophy (SMA), which increases the body’s ability to produce SMN protein critical to.

  • The good, the bad and the ugly The good, the bad and the ugly

    Tecfidera (MS) and Spinraza (Spinal Muscular Atrophy) are expected to generate big sales, while Tysabril (MS and Crohn’s Disease) and Avonex (MS) are expected to see sales drop due to

  • Europe vs the US: New drug product approvals Europe vs the US: New drug product approvals

    Among the noteworthy orphan approvals are Exondys 51 (for the treatment of Duchenne muscular dystrophy, only approved in the US), Darzalex (for the treatment of multiple myeloma, approved in the US ... 2015 and in the EU 2016) and Spinraza (for the

  • Deal Watch August 2016 Deal Watch August 2016

    95.  Ionis (US). Biogen (US). Exercise option .  Nusinersen, in phase III for treatment for spinal muscular atrophy.

More from intelligence
Approximately 0 fully matching, plus 11 partially matching documents found.

Latest from PMHub

  • Raising Awareness: Rare Disease Day

    of, such as spinal muscular atrophy and lysosomal storage disorders.(3). ... confused for other diseases.(2) For example, the genetic disorder adrenomyeloneuropathy, characterized by progressive problems with the brain, spinal cord and peripheral nerves

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Healthcare Media Europe – HME Ltd

HME are an innovative and technology enabled agency offering our clients over 35+ years of knowledge and expertise in delivering...

Latest intelligence

London
“Brexit has been a catalyst for UK clinical research... it’s turbocharged change”
The UK clinical trials environment has been transformed in recent years – but can it really buck Brexit’s risks and uncertainties?...
The Future of Pharma sales: fast forward to 2029
Change is inevitable, and necessary, for growth in business....
International Women's Day - 8 March 2019
International Women's Day has been celebrated since its inception in 1911. But how far have we come?...

Infographics